The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: AMT-151 in Patients With Selected Advanced Solid Tumours
Official Title: First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Study ID: NCT05498597
Brief Summary: This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-151, a novel antibody-drug conjugate against folate receptor alpha, in patients with selected advanced solid tumors.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Chris O'Brien Lifehouse, Sydney, New South Wales, Australia
ICON Cancer Centre, Brisbane, Queensland, Australia
Mater Cancer Care Centre, South Brisbane, Queensland, Australia
Cancer Research SA, Adelaide, South Australia, Australia
Cabrini Malvern Hospital, Malvern, Victoria, Australia
One Clinical Research (OCR), Perth, Western Australia, Australia
Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China
Hunan Cancer Hospital, Changsha, Hunan, China
Shanghai Tumor Hospital, Shanghai, Shanghai, China
Name: Sarwan Bishnoi
Affiliation: Cancer Research SA
Role: PRINCIPAL_INVESTIGATOR
Name: Richardson Gary
Affiliation: Cabrini Malvern Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Steven Kao
Affiliation: Chris O'Brien Lifehouse
Role: PRINCIPAL_INVESTIGATOR
Name: Catherine Shannon
Affiliation: Mater Cancer Care Centre
Role: PRINCIPAL_INVESTIGATOR
Name: Jermaine Coward
Affiliation: ICON Cancer Centre
Role: PRINCIPAL_INVESTIGATOR
Name: Mihitha Ariyapperuma
Affiliation: One Clinical Research (OCR)
Role: PRINCIPAL_INVESTIGATOR